J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chrysant, S. G.
Right arrow Articles by Chrysant, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chrysant, S. G.
Right arrow Articles by Chrysant, G. S.

THERAPEUTIC REVIEW

Pharmacological and Clinical Profile of Moexipril: A Concise Review

Steven G. Chrysant, MD, PhD and George S. Chrysant, MD

From the University of Oklahoma and the Oklahoma Cardiovascular and Hypertension Center, Oklahoma City, Oklahoma (Dr. S. G. Chrysant) and the Washington University School of Medicine, Division of Cardiology, St. Louis, Missouri (Dr. G. S. Chrysant).

Angiotensin-converting enzyme (ACE) inhibitors are effective and safe antihypertensive drugs, with the exception of the rare occasion of angioedema. These drugs have demonstrated additional cardiovascular protective effects to their blood pressure lowering, and their combination with the diuretic hydrochlorothiazide potentiates their antihypertensive effectiveness. Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylic metabolite, moexiprilat, to become effective. Moexipril alone and in combination with low-dose hydrochlorothiazide has been shown in clinical trials to be effective in lowering blood pressure and be well tolerated and safe given in single daily doses. In this review, the pharmacological profile of this drug and its clinical usefulness are discussed.

Key Words: Angiotensin converting enzyme (ACE) inhibitors • angiotensin II • hypertension • treatment • moexipril • hydrochlorothiazide

Address for reprints: Steven G. Chrysant, MD, PhD, 5850 W. Wilshire Boulevard, Oklahoma City, OK 73132-4904 (schrysant{at}yahoo.com).






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American College of Clinical Pharmacology